Neurofibromatosis Type 1: Understanding Craniofacial Plexiform Neurofibroma
"A Comprehensive Guide to Symptoms, Diagnosis, and Management"
Neurofibromatosis Type 1 (NF-1), also known as Von Recklinghausen's disease, is a genetic disorder that increases the risk of both benign and malignant tumors. Among these, plexiform neurofibromas (PNs) are a type of tumor that affects the peripheral nerve sheath. While relatively common, PNs can lead to significant health challenges and affect quality of life.
This article explores craniofacial plexiform neurofibromas, which occur in the head and face region. These tumors can cause a range of issues, including cosmetic disfigurement, pain, and nerve compression. Diagnosing and managing craniofacial PNs requires a thorough understanding of their characteristics and potential complications.
We'll delve into a case study of an 18-year-old female diagnosed with a craniofacial plexiform neurofibroma, highlighting the diagnostic process, clinical findings, and treatment considerations. This example will illustrate the complexities involved in managing this condition and underscore the importance of early detection and intervention.
A Variable Craniofacial Burden
Neurofibromatosis type 1 can affect multiple body systems, including the craniofacial region. The impact varies considerably between individuals, from relatively limited findings to complications that affect appearance, function, pain, or neurological health. Craniofacial plexiform neurofibroma therefore requires individualized assessment rather than a uniform expectation of disease severity.
Multidisciplinary Diagnosis and Care
NF1 has varied clinical features, so patients may present to different medical or surgical specialists and the connection between their symptoms and NF1 may not be recognized promptly. Diagnosis is generally clinical, although RNA-based NF1 mutation testing can help confirm it. Osseous manifestations occur in a minority of affected people but can cause substantial impairment, and craniofacial findings remain an area where published literature has been limited and partly contradictory.
An Evolving Clinical Understanding
Understanding of NF1 has developed through recognition of its diverse clinical manifestations and its inherited nature. Craniofacial plexiform neurofibroma represents one part of a broader disorder whose presentation can differ substantially among patients. Current interpretations continue to evolve as clinicians refine diagnostic and management approaches.
Understanding Craniofacial Plexiform Neurofibromas
Plexiform neurofibromas (PNs) are benign tumors that arise from the nerve sheath, the protective covering around nerves. In NF-1, these tumors can grow along the length of a nerve, involving multiple nerve bundles. This can lead to a "bag of worms" appearance, characterized by a convoluted mass of tissue.
- Spine
- Extremities
- Mediastinum
- Abdomen
Research Across Multiple Systems
Recent research describes NF1 as a common hereditary tumor-predisposition syndrome affecting multiple systems with unpredictable outcomes. Genotype-phenotype correlations remain incompletely understood and are not yet established. Reviews published in 2025 continue to examine NF1 clinical features, molecular mechanisms, potential treatments, and future research directions, while diagnostic criteria revised in 2021 remain part of contemporary clinical practice.
Uncommon Findings and Ongoing Complications
A 2025 case series illustrates uncommon craniofacial manifestations of NF1 on MRI, using two 3 T scanners: the GE Discovery MR750W and the Siemens Magnetom Vida. Such cases show why typical presentations may not capture the full range of craniofacial disease. More broadly, the Mayo Clinic notes that complications can include learning difficulties, heart and blood-vessel conditions, vision loss, and pain, so treatment must address complications as well as support healthy growth and development.
Distinguishing Related Terms and Imaging Needs
Neurofibroma and neurofibromatosis are related terms but are not equivalent: neurofibromas are tumors that can occur where nerves are present, whereas neurofibromatosis is a disorder affecting multiple organs and tissues. NF1 and NF2 are also distinct autosomal-dominant neurocutaneous disorders, despite sharing part of their name. A 2021 report on congenital craniofacial plexiform neurofibroma in NF1 demonstrates the use of different radiographical imaging modalities during diagnostic work-up.
Navigating the Challenges of Plexiform Neurofibromas
While plexiform neurofibromas are typically benign, they can cause significant challenges due to their potential for pain, disfigurement, and functional impairments. In rare cases, these tumors can undergo malignant transformation, making it difficult to predict the long-term prognosis.
Coordinated Care for a Multisystem Disorder
GeneReviews characterizes NF1 by findings including café au lait macules, intertriginous freckling, cutaneous neurofibromas, and learning or behavioral difficulties. It reports that about half of people with NF1 have plexiform neurofibromas, most of which are internal and not clinically suspected, and that these lesions can cause pain or neurological deficits. Because NF1 has diverse manifestations, comprehensive management requires attention from multiple specialties.
Expanding Therapeutic Strategies
Future NF1 therapeutics are being explored across several biological strategies. Preclinical development and early clinical trials include oncolytic viruses, cellular therapy, immune checkpoint inhibitors, gene therapy, and direct RAS inhibition. Two ongoing Phase 3 clinical trials based in the United States were identified in a January 2026 guidelines update as potentially relevant to future neurofibromatosis recommendations.
Interdisciplinary Challenges
Neurofibromatosis is not a single disorder but refers to three conditions involving tumors that may affect the brain, spinal cord, and peripheral nerves. NF1 can therefore present across multiple organs and tissues rather than within one narrowly defined specialty. Although substantial progress has been made, major challenges remain and a collaborative, interdisciplinary approach is required for management.
Living With Craniofacial Disease
Reports of massive plexiform neurofibromas in children with NF1 have been used to examine their natural history and real-world clinical impact. Craniofacial and oral alterations can be important parts of this experience, although the literature describing them has been characterized as limited and partly contradictory. These cases emphasize the need to understand both the physical course of disease and the practical consequences for affected children and families.
Given the progressive nature of NF-1, long-term follow-up is essential. The decision to pursue surgery or other treatment modalities should be carefully weighed against the potential benefits and risks, considering both the physical and psychological well-being of the patient.
Living with NF-1 and craniofacial plexiform neurofibromas requires a multidisciplinary approach, involving medical professionals, patients, and their families. With ongoing research and advancements in treatment, there is hope for improving the management and outcomes for individuals affected by this condition.